Home/Pulmocide/Matt Dallas

MD

Matt Dallas

Chief Financial Officer

Therapeutic Areas

Infectious Disease Pulmonology

Pulmocide Pipeline

Drug	Indication	Phase
Opelconazole (PC945)	Invasive Pulmonary Aspergillosis (refractory to standard care)	Phase 3

Leadership Team at Pulmocide

Chairman and Chief Executive Officer

Dr. Pete Strong

Chief Scientific Officer and Cofounder

Dr. Lance Berman

Chief Medical Officer

Jennifer Giottonini Cayer

Chief Business Officer and Head of Corporate Development

View full Pulmocide profile